2022
DOI: 10.1590/1678-4685-gmb-2022-0150
|View full text |Cite
|
Sign up to set email alerts
|

Clinical genomics and precision medicine

Abstract: Precision Medicine emerges from the genomic paradigm of health and disease. For precise molecular diagnoses of genetic diseases, we must analyze the Whole Exome (WES) or the Whole Genome (WGS). By not needing exon capture, WGS is more powerful to detect single nucleotide variants and copy number variants. In healthy individuals, we can observe monogenic highly penetrant variants, which may be causally responsible for diseases, and also susceptibility variants, associated with common polygenic diseases. But the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 43 publications
0
1
0
Order By: Relevance
“…Exploring biomarkers associated with aneurysms identified from routinely collected electronic health records might suffer from misclassification bias due to the asymptomatic nature of the disease. Genomics can provide unique data about an individual’s unique risk of disease [ 13 , 14 ] and genetic risks of aneurysms were stable and precise, which might assist in identifying robust biomarkers [ 15 , 16 ]. There have been several large-scale genome-wide association studies (GWAS) that report a potential shared genetic aetiology among the main types of aneurysms [ 17 21 ], including AAA, thoracic aortic aneurysm (TAA), intracranial aneurysm (ICA) and Marfan syndrome (MFS) in which the main complication is TAA [ 22 , 23 ].…”
Section: Introductionmentioning
confidence: 99%
“…Exploring biomarkers associated with aneurysms identified from routinely collected electronic health records might suffer from misclassification bias due to the asymptomatic nature of the disease. Genomics can provide unique data about an individual’s unique risk of disease [ 13 , 14 ] and genetic risks of aneurysms were stable and precise, which might assist in identifying robust biomarkers [ 15 , 16 ]. There have been several large-scale genome-wide association studies (GWAS) that report a potential shared genetic aetiology among the main types of aneurysms [ 17 21 ], including AAA, thoracic aortic aneurysm (TAA), intracranial aneurysm (ICA) and Marfan syndrome (MFS) in which the main complication is TAA [ 22 , 23 ].…”
Section: Introductionmentioning
confidence: 99%